Tax changes weaken case for new Pfizer bid, says AstraZeneca CEO

LONDON, Nov 6 (Reuters) - Recent U.S. tax changes have weakened the case for companies like Pfizer to shift their tax bases overseas by striking so-called tax inversion deals, according to AstraZeneca's chief executive.

from Reuters: Company News http://ift.tt/1xbMLNA

via IFTTT